Aandeel A222110 PANGEN BIOTECH INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen PanGen Biotech Inc.

Aandelen

A222110

KR7222110009

slotkoers Korea S.E.
Andere beurzen
 00:00:00 30-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
6.270 KRW -.--% Intraday-grafiek van PanGen Biotech Inc. +10,97% -8,87%
2023 PanGen Biotech Inc. rapporteert winstresultaten voor het eerste kwartaal eindigend op 31 maart 2023 CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
PanGen Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
PanGen Biotech Inc. announced that it has received KRW 3.2 billion in funding from Eugene Investment & Securities Co.,Ltd., Samsung Securities Co., Ltd.
PanGen Biotech Inc. announced that it expects to receive KRW 3.2 billion in funding from Eugene Investment & Securities Co.,Ltd., Samsung Securities Co., Ltd.
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.
PanGen Biotech Inc. announced that it has received KRW 9.99998571 billion in funding from Huons Co., Ltd. and another investor
PanGen Biotech Inc. announced that it expects to receive KRW 9.99998571 billion in funding from Huons Co., Ltd., and another investor
Huons Lab Forms Partnership with Pangen Biotech to Co-Develop Human Genetic Recombinant Hyaluronidase
PanGen Biotech Inc.(KOSDAQ:A222110) dropped from S&P Global BMI Index
CCM Duopharma Biotech Berhad completed the acquisition of 8.4% stake in PanGen Biotech Inc. from Chemical Company of Malaysia Berhad.
CCM Duopharma Biotech Berhad entered into agreement to acquire PanGen Biotech Inc. from Chemical Company of Malaysia Berhad for KRW 16.4 billion.
Chemical Companies In Talks To Sell Non Core Assets
PanGen Biotech Inc. announced that it has received KRW 18 billion in funding
PanGen Biotech Inc. announced that it expects to receive KRW 18 billion in funding
PanGen Biotech Inc.(KOSDAQ:A222110) added to S&P Global BMI Index
PanGen Biotech Inc. has completed an IPO in the amount of KRW 27.23 billion.
PanGen Biotech Inc. has filed an IPO in the amount of KRW 18.75 billion.
PanGen Biotech Inc. has withdrawn its IPO in the amount of KRW 35.40 billion.
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers A222110
  4. Nieuws PanGen Biotech Inc.
  5. Andere talen